See Remarks
Mark A. Goldsmith, M.D., Ph.D. is the Founding President, Chief Executive Officer, and Chair of the Board of Revolution Medicines, Inc. (RVMD), a clinical-stage oncology company focused on targeted cancer therapies.[[1]](https://nurabio.com/team/mark-goldsmith/)[[2]](https://fintool.com/app/research/companies/RVMD/people/mark-goldsmith)[[6]](https://www.revmed.com/team/mark-a-goldsmith-m-d-ph-d/) He has held these roles since November 2014 as CEO and director, becoming Chair in 2020.[[2]](https://fintool.com/app/research/companies/RVMD/people/mark-goldsmith) Goldsmith recently traded RVMD stock, selling 30,000 shares on November 7, 2025, for $1.8 million after exercising options, and gifting 150,000 shares on November 12, 2025.[[3]](https://www.investing.com/news/insider-trading-news/revolution-medicines-ceo-goldsmith-sells-18-million-in-stock-93CH-4353740) His 2024 total compensation was $10,079,491, including a $689,167 salary.[[5]](https://aflcio.org/paywatch/RVMD)
Goldsmith brings extensive biotechnology leadership experience, having previously served as Partner at Third Rock Ventures (2013–2015), President and CEO of Constellation Pharmaceuticals (2009–2012, later Chairman), first CEO of Global Blood Therapeutics and Nurix Therapeutics (both 2012–2014), CEO of Cogentus Pharmaceuticals, and Senior Vice President at Genencor International.[[1]](https://nurabio.com/team/mark-goldsmith/)[[2]](https://fintool.com/app/research/companies/RVMD/people/mark-goldsmith) Academically, he earned an AB from Princeton University and MD/PhD in microbiology and immunology from UCSF, followed by faculty positions at UCSF and the Gladstone Institute, with postgraduate training at Brigham and Women’s Hospital/Harvard and UCSF.[[1]](https://nurabio.com/team/mark-goldsmith/) He has co-authored 85 publications, holds multiple patents, and was elected to the American Society for Clinical Investigation and Association of American Physicians.[[1]](https://nurabio.com/team/mark-goldsmith/)
View full insider profile →
